The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

The present disclosure relates generally to generation of a recombinant enzyme with cyclization activity and its use for generating cyclic peptides as well as linear peptide conjugates.

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.

The invention provides a method termed protein retention ExM (proExM), in which proteins, rather than labels, are anchored to the swellable gel, using a cross-linking molecule. This proExM strategy can be used to perform nanoscale imaging of immunostained cells and tissues as well as samples expressing various FPs as fluorescent signals from genetically encoded fluorescent proteins and/or conventional fluorescently labeled secondary antibodies and streptavidin that are directly anchored to the gel are preserved even when subjected to the nonspecific proteolytic digestion.

A sample container system for use in a method for determining dietary fiber comprises a sample container and a magnetic mixer. The sample container has a floor and a rigid side-wall upstanding therefrom to together delimit a sample containing space, wherein the floor includes a porous filter portion. The magnetic mixer has at least one concentrically arranged rotor-stator, each of the at least one concentrically arranged rotor-stator including a rotor and a stator, the rotor and the stator defining therebetween an annular shear gap, the rotor configured to rotate relative to the stator, the stator including a stator body having a first plurality of openings therethrough, the rotor including a magnetic coupling and a rotor body having a second plurality of openings therethrough, the magnetic coupling configured to couple with and follow an externally generated rotating magnetic field to cause the rotor to rotate in relation to the stator.

According to one embodiment, a detection device includes a sensor element and a probe molecule. The probe molecule is immobilized at the sensor element. The probe molecule associates with a receptor exposed at a surface of a detection target. The sensor element detects cleavage of the receptor having associated with the probe molecule.

The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.

Provided herein is an optical biosensor for detecting a target bioanalyte in a sample. The biosensor includes: a porous silicon or alumina substrate having a surface and a detection agent immobilised on the surface. The detection agent includes a sensing domain and a signaling domain, the sensing domain having a linker capable of interacting with the target bioanalyte and the signaling domain having a luminescence donor and a luminescence acceptor wherein the luminescence donor and the luminescence acceptor are connected by the linker and are optically coupled in the absence of the target bioanalyte. Emission of light from the luminescence donor is substantially quenched by the luminescence acceptor, and interaction of the target bioanalyte with the linker results in optical un-coupling of the luminescence donor and the luminescence acceptor to thereby result in light emission from the luminescence donor.

Described herein are methods of using biomarker levels to detect proteins in a biological sample obtained from a patient with ovarian cancer, calculate a quantitative score for a patient with ovarian cancer, and predict a likelihood of a clinical outcome in a patient with ovarian cancer. The methods involve determining a level of at least three proteins in the biological sample obtained from the patient wherein the at least three proteins are selected from ANG-2, HE4, PROSTASIN, EGFR and IL-8, calculating a quantitative score for the patient by weighting the level of the at least three proteins by their contribution to a clinical outcome, and/or predicting a likelihood of a clinical outcome for the patient based on the quantitative score. Also provided are sets of reagents and test kits to the levels of the biomarkers described herein.

In one aspect, a homogenous assay method for determination of blood levels of legumain molecules (an asparaginyl endopeptidase) is disclosed. In one aspect, the assay utilizes specific sizes of nanoparticles that arc coated with antibody or antibodies specifically towards legumain molecule or its fragment(s). In one aspect, the assay is designed in a homogenous manner with a dynamic range from 0.2 to 160 ng/mL. In another aspect, disclosed herein is a kit for assaying blood levels of legumian comprising two parts of reagents (R1 and R2), which kit is adaptable to be used on clinical chemistry analyzers. In one aspect, the cut-off values for differentiating normal from high risk of cancers such as breast cancer, colorectal cancer and stomach cancer are 183 ng/mL.